Avanza Fonder Ab Mereo Biopharma Group PLC Put Options Transaction History
Avanza Fonder Ab
- $3.05 Trillion
- Q1 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding MREO
# of Institutions
97Shares Held
117MCall Options Held
199KPut Options Held
450K-
Janus Henderson Group PLC London, X022.7MShares$56.8 Million0.03% of portfolio
-
Rubric Capital Management LP New York, NY15.3MShares$38.3 Million0.99% of portfolio
-
Mangrove Partners New York, NY8.64MShares$21.6 Million3.05% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.71MShares$16.8 Million0.58% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD6.68MShares$16.7 Million0.9% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $312M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...